Shin Kadota1,2, John Carey3, Hans Reinecke1,2, James Leggett4, Sam Teichman4, Michael A Laflamme1,2, Charles E Murry1,2,5,6, Michael Regnier2,5, Gregory G Mahairas4. 1. Department of Pathology, Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA. 2. Center for Cardiovascular Biology, Institute for Stem Cell and Regenerative Medicine University of Washington, Seattle, WA, USA. 3. North American Science Associates Inc., Northwood, OH, USA. 4. BEAT Biotherapeutics Corp., Seattle, WA, USA. 5. Department of Bioengineering University of Washington, Seattle, WA, USA. 6. Department of Medicine/Cardiology, University of Washington, Seattle, WA, USA.
Abstract
AIMS: Heart failure remains a leading cause of morbidity, hospitalizations, and deaths. We previously showed that overexpression of the enzyme ribonucleotide reductase (RNR) in cardiomyocytes increased levels of the myosin activator, 2-deoxy-ATP, catalysed enhanced contraction, and improved cardiac performance in rodent hearts. Here we used a swine model of myocardial infarction (MI) to test preliminarily a novel gene therapy for heart failure based on delivery of the human RNR enzyme complex under the control of a cardiac-specific promoter via an adeno-associated virus serotype 6 vector--designated as BB-R12. METHODS AND RESULTS: We induced heart failure following MI in Yucatan minipigs by balloon occlusion of the left anterior descending artery. Two weeks, later, pigs received BB-R12 at one of three doses via antegrade coronary infusion. At 2 months post-treatment, LVEF and systolic LV dimension (measured by echocardiography) improved significantly in the high-dose group, despite further deterioration in the saline controls. Haemodynamic parameters including LV end-diastolic pressure, +dP/dt, and -dP/dt all trended towards improvement in the high-dose group. We observed no difference in the histopathological appearance of hearts or other organs from treated animals vs. controls, nor did we encounter any safety or tolerability concerns following BB-R12 delivery. CONCLUSION: These pilot results suggest cardiac-specific gene therapy using BB-R12 may reverse cardiac dysfunction by myosin activation in a large-animal heart failure model with no observed safety concerns. Thus further research into the therapeutic potential of BB-R12 for patients with chronic heart failure appears warranted.
AIMS: Heart failure remains a leading cause of morbidity, hospitalizations, and deaths. We previously showed that overexpression of the enzyme ribonucleotide reductase (RNR) in cardiomyocytes increased levels of the myosin activator, 2-deoxy-ATP, catalysed enhanced contraction, and improved cardiac performance in rodent hearts. Here we used a swine model of myocardial infarction (MI) to test preliminarily a novel gene therapy for heart failure based on delivery of the human RNR enzyme complex under the control of a cardiac-specific promoter via an adeno-associated virus serotype 6 vector--designated as BB-R12. METHODS AND RESULTS: We induced heart failure following MI in Yucatan minipigs by balloon occlusion of the left anterior descending artery. Two weeks, later, pigs received BB-R12 at one of three doses via antegrade coronary infusion. At 2 months post-treatment, LVEF and systolic LV dimension (measured by echocardiography) improved significantly in the high-dose group, despite further deterioration in the saline controls. Haemodynamic parameters including LV end-diastolic pressure, +dP/dt, and -dP/dt all trended towards improvement in the high-dose group. We observed no difference in the histopathological appearance of hearts or other organs from treated animals vs. controls, nor did we encounter any safety or tolerability concerns following BB-R12 delivery. CONCLUSION: These pilot results suggest cardiac-specific gene therapy using BB-R12 may reverse cardiac dysfunction by myosin activation in a large-animal heart failure model with no observed safety concerns. Thus further research into the therapeutic potential of BB-R12 for patients with chronic heart failure appears warranted.
Authors: Michael G Katz; Anthony S Fargnoli; JaBaris D Swain; Catherine E Tomasulo; Michele Ciccarelli; Z Maggie Huang; Joseph E Rabinowitz; Charles R Bridges Journal: J Thorac Cardiovasc Surg Date: 2011-12-03 Impact factor: 5.209
Authors: Kiyotake Ishikawa; Kenneth M Fish; Lisa Tilemann; Kleopatra Rapti; Jaume Aguero; Carlos G Santos-Gallego; Ahyoung Lee; Ioannis Karakikes; Chaoqin Xie; Fadi G Akar; Yuichi J Shimada; Judith K Gwathmey; Aravind Asokan; Scott McPhee; Jade Samulski; Richard Jude Samulski; Daniel C Sigg; Thomas Weber; Evangelia G Kranias; Roger J Hajjar Journal: Mol Ther Date: 2014-07-15 Impact factor: 11.454
Authors: Bradley P Morgan; Alexander Muci; Pu-Ping Lu; Xiangping Qian; Todd Tochimoto; Whitney W Smith; Marc Garard; Erica Kraynack; Scott Collibee; Ion Suehiro; Adam Tomasi; S Corey Valdez; Wenyue Wang; Hong Jiang; James Hartman; Hector M Rodriguez; Raja Kawas; Sheila Sylvester; Kathleen A Elias; Guillermo Godinez; Kenneth Lee; Robert Anderson; Sandra Sueoka; Donghong Xu; Zhengping Wang; Nebojsa Djordjevic; Fady I Malik; David J Morgans Journal: ACS Med Chem Lett Date: 2010-08-20 Impact factor: 4.345
Authors: John R Teerlink; Cyril P Clarke; Khalil G Saikali; Jacqueline H Lee; Michael M Chen; Rafael D Escandon; Lyndsey Elliott; Rachel Bee; Mohammad Reza Habibzadeh; Jonathan H Goldman; Nelson B Schiller; Fady I Malik; Andrew A Wolff Journal: Lancet Date: 2011-08-20 Impact factor: 79.321
Authors: Sarah G Nowakowski; Stephen C Kolwicz; Frederick Steven Korte; Zhaoxiong Luo; Jacqueline N Robinson-Hamm; Jennifer L Page; Frank Brozovich; Robert S Weiss; Rong Tian; Charles E Murry; Michael Regnier Journal: Proc Natl Acad Sci U S A Date: 2013-03-25 Impact factor: 11.205
Authors: Krisztina Zsebo; Alex Yaroshinsky; Jeffrey J Rudy; Kim Wagner; Barry Greenberg; Mariell Jessup; Roger J Hajjar Journal: Circ Res Date: 2013-09-24 Impact factor: 17.367
Authors: Farid Moussavi-Harami; Maria V Razumova; Alice W Racca; Yuanhua Cheng; April Stempien-Otero; Michael Regnier Journal: J Mol Cell Cardiol Date: 2014-12-10 Impact factor: 5.000
Authors: Joseph D Powers; Chen-Ching Yuan; Kimberly J McCabe; Jason D Murray; Matthew Carter Childers; Galina V Flint; Farid Moussavi-Harami; Saffie Mohran; Romi Castillo; Carla Zuzek; Weikang Ma; Valerie Daggett; Andrew D McCulloch; Thomas C Irving; Michael Regnier Journal: Proc Natl Acad Sci U S A Date: 2019-05-20 Impact factor: 11.205
Authors: David Lopez; Jonathan A Pan; Peter M Pollak; Samantha Clarke; Christopher M Kramer; Mark Yeager; Michael Salerno Journal: NMR Biomed Date: 2017-02-06 Impact factor: 4.044
Authors: Stephen C Kolwicz; Guy L Odom; Sarah G Nowakowski; Farid Moussavi-Harami; Xiaolan Chen; Hans Reinecke; Stephen D Hauschka; Charles E Murry; Gregory G Mahairas; Michael Regnier Journal: Mol Ther Date: 2015-09-21 Impact factor: 11.454
Authors: Mike Woodward; Eric Ostrander; Seung P Jeong; Xiarong Liu; Brent Scott; Matt Unger; Jianhan Chen; Dhandapani Venkataraman; Edward P Debold Journal: Biophys J Date: 2020-06-30 Impact factor: 4.033
Authors: Stephen C Kolwicz; John K Hall; Farid Moussavi-Harami; Xiolan Chen; Stephen D Hauschka; Jeffrey S Chamberlain; Michael Regnier; Guy L Odom Journal: JACC Basic Transl Sci Date: 2019-10-02